Aurefluidics Technology Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $13.7M

  • Investors
  • 7

Aurefluidics Technology General Information

Description

Developer of microfluidic devices designed for biomedical applications. The company's platform integrates CMOS-MEMS inkjet printing chips, microfluidic design, cell printing, temperature control, and system integration, enabling researchers and healthcare professionals to advance drug development, diagnostics, and treatment through high-performance and reliable microfluidic solutions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 401, 4th Floor, North Building, Building 3
  • No. 333 Huangqing Road, Jiading District
  • Shanghai, 200180
  • China
+86 021
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • Room 401, 4th Floor, North Building, Building 3
  • No. 333 Huangqing Road, Jiading District
  • Shanghai, 200180
  • China
+86 021

Aurefluidics Technology Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurefluidics Technology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B1) 22-Jan-2025 $13.7M Completed Generating Revenue
3. Later Stage VC 13-Nov-2023 Completed Generating Revenue
2. Early Stage VC 01-Sep-2021 Completed Generating Revenue
1. Early Stage VC 01-Apr-2019 Completed Generating Revenue
To view Aurefluidics Technology’s complete valuation and funding history, request access »

Aurefluidics Technology Patents

Aurefluidics Technology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023201942-A1 Single-cell sorting microfluidic chip and single-cell sorting method Inactive 22-Apr-2022
JP-2025511210-A Microfluidic chip and method for culturing single cells and sorting and extracting cell populations - patents.com Active 31-Mar-2022
JP-7909615-B2 Microfluidic chip and method for culturing single cells and sorting and extracting cell populations. Active 31-Mar-2022
EP-4506443-A1 Microfluidic chip and methods for culturing single cell and screening and exporting cell population Pending 31-Mar-2022
EP-4506443-A4 Microfluidic chip and methods for culturing single cell and screening and exporting cell population Pending 31-Mar-2022 G01N33/5047
To view Aurefluidics Technology’s complete patent history, request access »

Aurefluidics Technology Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Xingcheng Capital Growth/Expansion Minority
Hopesun Capital PE/Buyout Minority
MGI Tech Corporation Minority
Origins Capital Venture Capital Minority
Xiamen Hi-Tech Innovation Center Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Aurefluidics Technology FAQs

  • When was Aurefluidics Technology founded?

    Aurefluidics Technology was founded in 2018.

  • Where is Aurefluidics Technology headquartered?

    Aurefluidics Technology is headquartered in Shanghai, China.

  • What industry is Aurefluidics Technology in?

    Aurefluidics Technology’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Aurefluidics Technology a private or public company?

    Aurefluidics Technology is a Private company.

  • What is Aurefluidics Technology’s current revenue?

    The current revenue for Aurefluidics Technology is .

  • How much funding has Aurefluidics Technology raised over time?

    Aurefluidics Technology has raised $13.7M.

  • Who are Aurefluidics Technology’s investors?

    Xingcheng Capital, Hopesun Capital, MGI Tech, Origins Capital, and Xiamen Hi-Tech Innovation Center are 5 of 7 investors who have invested in Aurefluidics Technology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process